Mufemilast
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Mufemilast
- Molecular weight
- 466.54
- Structure (SMILES)
- CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3csc(NC(C)=O)c3C2=O)ccc1OC
- 15mg hemay005
- 15mg Hemay005
- 60mg Hemay005
- hemay 005
- HEMAY-005
- hemay005
- Hemay005
- HEMAY005
- Hemay005 60 mg
- Hemay005 tablet
- Hemay005 tablets
- mufemilast
- Mufemilast
- mufemilast [INN]
- Mufemilast [WHO-DD]
- mufemilast inn
- mufemilast who dd
- CAS registry numbers
- 1255909-03-5
- ChEMBL ID
- CHEMBL5095240
- InChIKey
- PRSNGWLHNWGOKD-CQSZACIVSA-N
- PubChem compound IDs
- 137355584
- FDA ingredient codes (UNII)
- 4QX9BK9E7P
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mufemilast
- Type
- Synthetic organic
- Drug name stem
- -ast
- Approval recorded by Guide to Pharmacology
- Yes
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Psoriasis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Behcet Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003780
- Subject identifier
- D001528
- Condition
- Spondylitis, Ankylosing
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003898
- Subject identifier
- D013167
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003780
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003898
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 3
- Condition identifier
- HP_0000155
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005306
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007191
- Highest recorded phase
- 3
- NCT03007810
- NCT03570346
- NCT03577626
- NCT04102241
- NCT04837235
- NCT04839328
- NCT06376474
- NCT06380153
- NCT04609397
- NCT05407246
- NCT05486104
- NCT05769946
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 119.08
- Calculated partition coefficient (ALogP)
- 2.5
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 31
- Molecular formula
- C20H22N2O7S2
- Monoisotopic mass
- 466.08684339
- Natural product
- No
- Recorded assays
- 5
- Active assays
- 5
Active assay types
- Confirmatory
- Dermatologic Agents
- Phosphodiesterase 4 Inhibitors
Related records
Trials (20)
- A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers
- A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- A Study of Hemay005 in Adult With Atopic Dermatitis
- A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers
- A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
- A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
- Bioequivalence Test of Hemay005 Tablets
- Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
- Evaluation the Safety of hemay005 Tablets
- Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
- In Vivo Mass Balance Study of [14C]Hemay005
- Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
- Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
- Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets
- Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
- Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
- Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
In development for (5)
- Ankylosing spondylitis Phase 2
- Atopic eczema Phase 2
- Behcet disease Phase 2
- Psoriasis Phase 3
- Ulcerative colitis Phase 2